GlassScriptPhysician profile
Colette D Lieber
NPI 1396844163
$9,723.26
in general payments reported to CMS, 2019-2025
39 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $644 · 2021: $1,799 · 2022: $1,712 · 2023: $1,979 · 2024: $1,047 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,245 · Education: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.49 |
| Education | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,179.07 | 2019-2025 | Olumiant, Taltz, Zepbound |
| Genzyme Corporation | $950.53 | 2021-2022 | |
| Amgen INC. | $899.62 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $897.16 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $507.66 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Incyte Corporation | $466.86 | 2021-2024 | Opzelura |
| Journey Medical Corporation | $446.75 | 2019-2025 | |
| Epi Health, LLC | $433.60 | 2019-2022 | |
| Abbvie INC. | $428.51 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $398.28 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $397.08 | 2021-2025 | Odomzo, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $356.62 | 2019-2024 | Libtayo, Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.55 | 2023-2025 | Spevigo |
| Leo Pharma INC. | $244.21 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $235.60 | 2023-2024 | Sotyktu |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $202.30 | 2019-2024 | Tremfya |
| Galderma Laboratories, L.P. | $201.04 | 2020-2025 | Aklief |
| Ucb, INC. | $188.98 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $172.02 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $137.05 | 2023 | Ycanth |
| Mayne Pharma Commercial LLC | $122.28 | 2019-2025 | |
| Almirall LLC | $109.04 | 2019-2025 | Klisyri |
| Bausch & Lomb Americas INC. | $100.17 | 2022 | |
| Encore Dermatology INC. | $40.80 | 2019 | |
| Prugen, INC. Pharmaceuticals | $36.77 | 2019 | |
| Botanix Sb INC | $36.08 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $29.29 | 2020 | |
| Sandoz INC. | $27.91 | 2020-2021 | |
| Promius Pharma LLC | $27.70 | 2019 | |
| Celgene Corporation | $26.37 | 2019 | |
| Biofrontera INC. | $25.82 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $24.79 | 2020 | |
| Merck Sharp & Dohme LLC | $18.48 | 2024 | Keytruda |
| Sanofi-Aventis U.S. LLC | $18.44 | 2024 | |
| Lnhc, INC | $16.40 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $12.50 | 2022 | |
| Genentech USA, INC. | $12.22 | 2019 | |
| Mission Pharmacal Company | $12.02 | 2021 | |
| Dermira, INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colette Lieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.